Recombinant Austrelaps superbus Asurin-2

What is Recombinant Austrelaps superbus Asurin-2?

Recombinant Austrelaps superbus Asurin-2 is a laboratory-produced version of a cysteine-rich venom protein naturally found in the Lowland copperhead snake (Austrelaps superbus). This protein belongs to the CRISP (Cysteine-Rich Secretory Protein) family and is designated as a cysteine-rich venom protein in official classifications . The recombinant form is produced using various expression systems to enable scientific research without requiring direct venom extraction from snakes. Typically available as a lyophilized powder, Recombinant Asurin-2 maintains the key structural and functional characteristics of the native protein while allowing for controlled production, consistent quality, and potential modifications for specific research applications. The protein is typically marketed with a purity exceeding 85% as determined by SDS-PAGE analysis, making it suitable for a wide range of experimental applications.

How is Recombinant Austrelaps superbus Asurin-2 produced?

Recombinant Austrelaps superbus Asurin-2 production involves a multi-stage biotechnological process that begins with gene identification and cloning. The coding sequence for Asurin-2 is inserted into an appropriate expression vector containing necessary genetic elements for protein expression. This recombinant vector is then introduced into the chosen host organism - commonly E. coli, yeast, insect cells via baculovirus, or mammalian cells. The host organism is cultured under conditions optimized for protein expression, followed by harvesting and extraction procedures. The expressed protein undergoes multiple purification steps, typically involving chromatographic techniques like affinity chromatography and size-exclusion chromatography, to achieve the specified purity level of >85% as determined by SDS-PAGE. The purified protein solution is then lyophilized to create a stable powder form suitable for storage and distribution. Each expression system offers distinct advantages in terms of protein folding, post-translational modifications, and yield, allowing researchers to select the most appropriate form for their specific experimental requirements.

What expression systems are used for producing Recombinant Asurin-2?

Recombinant Austrelaps superbus Asurin-2 is produced using four primary expression systems, each offering distinct advantages for different research applications. The E. coli bacterial expression system provides cost-effectiveness and high yield, making it suitable for applications not requiring complex post-translational modifications . Yeast expression systems (such as Pichia pastoris) offer improved protein folding and some post-translational modifications while maintaining relatively high yields. The baculovirus expression system using insect cells provides more sophisticated post-translational modifications and proper folding of complex proteins with disulfide bonds, which is particularly important for cysteine-rich proteins like Asurin-2. Finally, mammalian cell expression systems deliver the most authentic post-translational modifications and proper protein folding, though at higher cost and lower yields than other systems. Commercial suppliers typically offer Recombinant Asurin-2 from multiple expression systems, allowing researchers to select the version most appropriate for their specific experimental requirements based on the degree of structural authenticity needed.

How should Recombinant Austrelaps superbus Asurin-2 be reconstituted for experiments?

Proper reconstitution of lyophilized Recombinant Austrelaps superbus Asurin-2 is critical for maintaining protein integrity and biological activity. The recommended protocol begins with briefly centrifuging the vial to ensure all material is at the bottom before opening. The lyophilized protein should be reconstituted in sterile deionized water to achieve a concentration between 0.1-1.0 mg/mL. The water should be added slowly, allowing the protein to dissolve gradually while avoiding vigorous vortexing or shaking that could cause protein denaturation. For experiments requiring extended use, adding glycerol to a final concentration of 5-50% is recommended, followed by preparation of single-use aliquots to minimize freeze-thaw cycles. Working aliquots are stable at 4°C for up to one week, but repeated freeze-thaw cycles should be avoided as they can compromise protein structure and activity. For applications requiring sterility, the reconstituted protein may be filtered through a 0.2 μm filter. Following reconstitution, protein concentration should be verified using established methods such as Bradford assay, BCA protein assay, or spectrophotometric measurement to ensure accurate dosing in experimental procedures.

What analytical methods are suitable for characterizing Recombinant Asurin-2?

Multiple analytical methods can be employed to thoroughly characterize Recombinant Austrelaps superbus Asurin-2, each providing specific information about the protein's properties. SDS-PAGE analysis under both reducing and non-reducing conditions is fundamental for assessing purity (typically >85%), molecular weight, and disulfide bond patterns . Mass spectrometry techniques provide precise molecular weight determination and can identify post-translational modifications, with variations expected depending on the expression system used (E. coli, yeast, baculovirus, or mammalian cells). Circular dichroism spectroscopy can evaluate secondary structure content and thermal stability, which is particularly important for cysteine-rich proteins like Asurin-2 that depend on proper disulfide bond formation. Size-exclusion chromatography, often coupled with multi-angle light scattering (SEC-MALS), can assess the oligomeric state and detect potential aggregation. For functional characterization, binding assays using surface plasmon resonance or enzyme-linked immunosorbent assays can determine interaction specificity and affinity constants. Western blotting with specific antibodies can confirm identity and detect potential degradation products. A comprehensive characterization strategy would employ multiple complementary techniques to generate a complete profile of the recombinant protein's structural and functional properties.

What are optimal storage conditions for Recombinant Austrelaps superbus Asurin-2?

Optimal storage conditions for Recombinant Austrelaps superbus Asurin-2 are essential for maintaining protein stability and biological activity throughout the research process. In its lyophilized form, the protein should be stored at -20°C or lower and protected from humidity. Once reconstituted, working aliquots can be maintained at 4°C for up to one week. For longer-term storage of reconstituted protein, it is critical to add glycerol to a final concentration of 5-50% and prepare single-use aliquots to avoid repeated freeze-thaw cycles that can significantly degrade protein quality. These aliquots should be stored at -20°C or preferably -80°C for extended stability. When removing aliquots from frozen storage, they should be thawed completely at 4°C before use, avoiding rapid temperature changes that can denature the protein. For transportation, the protein should be shipped with ice packs to maintain appropriate temperature. Researchers should document the preparation date, concentration, buffer composition, and freeze-thaw history for each aliquot to ensure experimental reproducibility. These storage practices are crucial for maintaining the structural integrity of cysteine-rich proteins like Asurin-2, where disulfide bond integrity is essential for biological activity.

What are the known biological activities of Asurin-2?

Based on its classification as a cysteine-rich venom protein (CRVP) in the CRISP family, Austrelaps superbus Asurin-2 likely exhibits several important biological activities, though specific studies on this particular protein variant may be limited . CRISPs from snake venoms frequently function as ion channel modulators, particularly affecting calcium-activated potassium channels and voltage-gated calcium channels. This ion channel modulation can result in neuromuscular effects, potentially influencing smooth muscle contraction or relaxation and neuronal signaling. The protein may also possess enzymatic activities, similar to other components in Austrelaps superbus venom such as phospholipases A2 (like the phospholipase A2 isozyme S2-22 and superbin c) . Additionally, some venom CRISPs demonstrate immunomodulatory properties comparable to the adjuvant activity observed with other recombinant venom proteins like rOv-ASP-1 . This adjuvant activity could enhance immune responses to co-administered antigens, potentially stimulating both Th1 and Th2 responses . The specific biological profile of Asurin-2 would require dedicated functional studies, as activities can vary even among closely related CRISP family proteins. The multifunctional nature of snake venom proteins suggests Asurin-2 may have additional undiscovered biological activities of scientific and potential therapeutic interest.

How does recombinant Asurin-2 compare to native Asurin-2 in functional assays?

Comparing recombinant and native Asurin-2 is essential for validating the recombinant protein as an accurate research tool. Several key differences typically exist between recombinant and native forms, particularly in post-translational modifications. The choice of expression system significantly influences these differences: E. coli-expressed Asurin-2 lacks glycosylation and may have incomplete or incorrect disulfide bonding, while yeast systems may produce hyperglycosylated variants. Baculovirus and mammalian expression systems generally yield proteins with post-translational modifications more similar to the native form. These structural differences can translate to functional variations in specific activity, with recombinant proteins often showing lower potency than native counterparts. Binding kinetics, measured by techniques like surface plasmon resonance, may reveal altered association and dissociation constants. The thermal and pH stability profiles can also differ between recombinant and native forms. For comprehensive comparison, researchers should conduct side-by-side functional assays under identical conditions, structural analysis using techniques like circular dichroism or X-ray crystallography, and detailed mass spectrometry analysis to identify post-translational modification differences. Such comparisons are crucial for determining whether the recombinant protein is an appropriate substitute for the native form in specific research applications.

What potential research applications exist for Recombinant Austrelaps superbus Asurin-2?

Recombinant Austrelaps superbus Asurin-2 has diverse potential applications across multiple scientific disciplines. In neuroscience research, it could serve as a tool for investigating ion channel modulation mechanisms, particularly for calcium-activated potassium channels and voltage-gated calcium channels, similar to other cysteine-rich venom proteins . Pharmacologically, it may function as a lead compound for developing novel therapeutics targeting specific ion channels or as a platform for structure-activity relationship studies in drug discovery pipelines. Structural biologists could utilize the protein for crystallization and structure determination studies to better understand the CRISP family's molecular architecture and disulfide bond patterns . Immunological applications include potential adjuvant properties similar to those observed with other venom-derived proteins like rOv-ASP-1, which has shown ability to enhance both Th1 and Th2 immune responses to co-administered antigens . In toxinology, Asurin-2 could provide insights into venom evolution and function. Biotechnological applications might include development of biosensors or engineered proteins with modified activities. The protein could also serve as an important tool in comparative studies with other venom components from Austrelaps superbus, such as the related phospholipase A2 proteins , contributing to a comprehensive understanding of this venomous species' biochemical arsenal.

How can inconsistent results with Recombinant Asurin-2 be troubleshooted?

Inconsistent results when working with Recombinant Austrelaps superbus Asurin-2 require systematic troubleshooting. Begin with reassessing protein quality through SDS-PAGE verification of purity (which should be >85%) , concentration verification using multiple methods, and examination for potential degradation products using western blotting. Storage conditions should be carefully evaluated, as improper handling can significantly impact protein integrity; working aliquots should not be stored at 4°C for more than one week, and repeated freeze-thaw cycles must be avoided. Buffer composition can significantly influence activity, so testing different formulations may resolve inconsistencies. The expression system source (E. coli, yeast, baculovirus, or mammalian cells) should be considered, as each provides different post-translational modifications that may affect function. Technical variables like equipment calibration, pipetting technique, and environmental factors should be standardized. For functional assays, include appropriate positive and negative controls, establish time-course profiles to determine optimal incubation periods, and consider concentration-dependent effects that might produce non-linear responses. When switching between batches, perform side-by-side comparisons to establish equivalence. Implement rigorous documentation practices recording protein batch information, storage history, and all experimental conditions to identify patterns in variability. This systematic approach not only resolves inconsistencies but also enhances understanding of the protein's behavior under various experimental conditions.

What is the molecular structure and classification of Asurin-2?

Asurin-2 from Austrelaps superbus is classified as a cysteine-rich venom protein (CRVP) belonging to the CRISP (Cysteine-Rich Secretory Protein) family . In protein databases, it is specifically identified as "Cysteine-rich venom protein asurin-2" . The protein is characterized by a high number of conserved cysteine residues that form disulfide bridges, which are critical for maintaining its three-dimensional structure and biological activity. While the complete three-dimensional structure of Asurin-2 has not been fully characterized in the available search results, it likely shares the canonical CRISP fold consisting of an N-terminal PR-1 (Pathogenesis-related protein-1) domain and a C-terminal cysteine-rich domain (CRD). This structural arrangement typically results in a compact protein with both α-helical and β-sheet elements. The specific pattern of disulfide bonds creates a stable tertiary structure that is essential for the protein's function, particularly for potential ion channel interactions. The recombinant forms of Asurin-2 are produced as fragments of the complete protein, which may represent functional domains or regions selected for optimal expression and activity. Post-translational modifications like glycosylation are likely present in the native protein, and their presence in recombinant versions would depend on the expression system used.

What methodologies are recommended for studying the adjuvant properties of Asurin-2?

Although specific adjuvant properties of Asurin-2 are not directly documented in the search results, research methodologies can be adapted from studies of similar proteins like rOv-ASP-1, another recombinant venom-derived protein with demonstrated adjuvant activity . To evaluate potential adjuvant properties of Recombinant Austrelaps superbus Asurin-2, researchers should first ensure the protein is free from endotoxin contamination through appropriate treatment methods similar to the Detoxi-gel system used for rOv-ASP-1 . Immunization protocols should involve subcutaneous administration of test antigens (such as ovalbumin) mixed with Asurin-2 at controlled dosages (e.g., 25 μg per mouse), followed by one or more booster immunizations at 14-day intervals . Immune responses should be evaluated through measurement of antigen-specific antibody titers, with particular attention to IgG isotype profiles (IgG1, IgG2a) to determine Th1/Th2 balance . ELISA methods can quantify these antibody responses, and comparison with established adjuvants like alum or MPL+TDM would provide context for Asurin-2's adjuvant potency . Cellular immune responses should be assessed through cytokine profiling of stimulated spleen cells, particularly examining Th1 (IFN-γ, IL-2) and Th2 (IL-4, IL-5) cytokines . Side-by-side comparisons using different antigen types, including peptides and polypeptides, would determine whether Asurin-2's adjuvant effects are antigen-dependent. These methodologies would systematically evaluate Asurin-2's potential as an adjuvant for various research and potentially therapeutic applications.

What protein engineering approaches can optimize Recombinant Asurin-2 for specific applications?

Protein engineering approaches can significantly enhance Recombinant Austrelaps superbus Asurin-2 for targeted research applications. Site-directed mutagenesis can be employed to modify specific amino acid residues, particularly to investigate structure-function relationships by altering cysteine residues involved in disulfide bond formation. Expression system selection is critical - while E. coli systems provide high yields, they lack post-translational modifications; conversely, mammalian expression systems provide authentic modifications but at lower yields. For improved purification and detection, genetic fusion with affinity tags (His, GST) or epitope tags (FLAG, HA) can be incorporated. Domain swapping with related CRISP family proteins could create chimeric proteins with novel functional properties. To enhance stability, researchers might introduce stabilizing mutations or optimize buffer formulations. Expression of truncated fragments, as seen in commercial preparations, can isolate functional domains for specific applications. For investigating binding mechanisms, fluorescent protein fusions or site-specific chemical labeling approaches can be implemented. To improve solubility and reduce aggregation, solubility-enhancing tags like MBP can be utilized. Each engineering approach should be validated through comparative functional assays to ensure the modified protein retains or enhances the desired properties while maintaining proper folding and stability. These strategies allow researchers to develop customized versions of Asurin-2 optimized for specific experimental objectives.

What are the recommended protocols for assessing Asurin-2's effects on ion channels?

Assessment of Recombinant Austrelaps superbus Asurin-2's effects on ion channels requires specialized electrophysiological techniques. Patch-clamp recording represents the gold standard methodology, allowing direct measurement of ion channel currents in various configurations (whole-cell, single-channel, or inside-out/outside-out patches). For high-throughput screening, automated patch-clamp systems can evaluate Asurin-2's effects across multiple channel types. Fluorescence-based assays using calcium-sensitive dyes (Fluo-4, Fura-2) or voltage-sensitive dyes can provide indirect measurements of channel activity in cell populations. Cell lines stably expressing specific ion channel types of interest should be established, particularly focusing on calcium-activated potassium channels and voltage-gated calcium channels that are typical targets of CRISP proteins. Dose-response relationships should be established by testing multiple concentrations of Asurin-2 (typically ranging from nanomolar to micromolar) to determine IC50/EC50 values. Competition assays with known channel blockers can help elucidate binding sites and mechanisms. For mechanistic studies, site-directed mutagenesis of specific channel residues can identify critical interaction points. Comparison of Asurin-2's effects across different expression systems (E. coli, yeast, baculovirus, and mammalian cells) can reveal the importance of post-translational modifications for channel interaction. Molecular dynamics simulations and in silico docking studies can complement experimental approaches by predicting binding modes and interaction energies. These methodologies collectively provide comprehensive characterization of Asurin-2's ion channel modulatory properties.

How might Recombinant Asurin-2 be utilized in immunological research beyond traditional adjuvant applications?

Recombinant Austrelaps superbus Asurin-2 offers multiple innovative applications in immunological research beyond traditional adjuvant roles. As a structurally complex CRISP family protein , Asurin-2 could serve as a model antigen for studying antigen processing and presentation pathways, particularly examining how proteins with extensive disulfide bonding are processed by antigen-presenting cells. The protein might be utilized to investigate mechanisms of immune tolerance to venom proteins, providing insights into how venomous animals maintain self-tolerance to their own toxins. For antibody development research, Asurin-2 could serve as a challenging target for generating conformation-specific antibodies, advancing techniques for producing antibodies against structurally complex antigens. Comparative studies using Asurin-2 expressed in different systems (E. coli, yeast, baculovirus, and mammalian cells) could illuminate how post-translational modifications influence immunogenicity and immune recognition. Drawing from research on related proteins like rOv-ASP-1 , Asurin-2 might be investigated for its capacity to modulate specific immune cell populations such as dendritic cells or T-cell subsets. In vaccine development, Asurin-2 could be explored as a carrier protein for conjugate vaccines, potentially enhancing immune responses to poorly immunogenic antigens. These applications extend beyond traditional adjuvant roles to leverage Asurin-2's unique structural and functional properties for advancing fundamental immunological research and applied vaccine technology.

What emerging technologies could enhance the study and application of Recombinant Asurin-2?

Emerging technologies offer transformative approaches for studying and applying Recombinant Austrelaps superbus Asurin-2. CRISPR/Cas9 genome editing enables precise modification of host expression systems to optimize post-translational modifications, potentially creating expression platforms that more accurately reproduce native Asurin-2's structure. Cell-free protein synthesis systems provide rapid production alternatives that bypass cellular toxicity issues and allow for incorporation of non-canonical amino acids. Advanced structural biology techniques including cryo-electron microscopy and AlphaFold-based computational prediction can reveal Asurin-2's three-dimensional structure at unprecedented resolution, illuminating structure-function relationships. Single-molecule techniques such as FRET and atomic force microscopy enable real-time visualization of Asurin-2's interactions with targets like ion channels. Microfluidic platforms can facilitate high-throughput screening of Asurin-2 variants against multiple targets simultaneously. Nanobody development against specific Asurin-2 epitopes offers new tools for tracking and modulating the protein's activity in complex systems. Advanced glycoengineering approaches can produce homogeneous glycoforms to study glycosylation's impact on function. Organ-on-a-chip technologies provide physiologically relevant platforms for testing Asurin-2's effects on integrated tissue systems. RNA sequencing and proteomics analyses can comprehensively profile cellular responses to Asurin-2 treatment, revealing previously unknown mechanisms of action. These emerging technologies collectively enhance our ability to understand, produce, and utilize Asurin-2 for both fundamental research and potential therapeutic applications.